Danaher Corporation $DHR Shares Sold by Mn Services Vermogensbeheer B.V.

Key Points

• Mn Services Vermogensbeheer B.V. reduced its stake in Danaher Corporation by 6.4%, selling 16,500 shares during the 2nd quarter, and now owns 240,700 shares valued at approximately $47.5 million.
• Danaher reported a quarterly earnings per share of $1.80, exceeding expectations, along with a revenue of $5.94 billion, reflecting a 3.4% year-over-year increase.
• The company declared a quarterly dividend of $0.32 per share, with an annualized yield of 0.7%, scheduled for payment on October 31st.

Mn Services Vermogensbeheer B.V. reduced its position in Danaher Corporation (NYSE:DHR - Free Report) by 6.4% during the second quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 240,700 shares of the conglomerate's stock after selling 16,500 shares during the period. Mn Services Vermogensbeheer B.V.'s holdings in Danaher were worth $47,548,000 at the end of the most recent quarter.

A number of other institutional investors have also modified their holdings of the company. Vanguard Group Inc. boosted its holdings in shares of Danaher by 0.4% in the 1st quarter. Vanguard Group Inc. now owns 59,981,088 shares of the conglomerate's stock valued at $12,296,123,000 after buying an additional 230,966 shares in the last quarter. Price T Rowe Associates Inc. MD boosted its holdings in shares of Danaher by 3.2% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 19,592,211 shares of the conglomerate's stock valued at $4,016,404,000 after buying an additional 612,154 shares in the last quarter. Bank of New York Mellon Corp boosted its holdings in shares of Danaher by 2.3% in the 1st quarter. Bank of New York Mellon Corp now owns 8,783,485 shares of the conglomerate's stock valued at $1,800,614,000 after buying an additional 194,466 shares in the last quarter. Invesco Ltd. boosted its holdings in shares of Danaher by 44.5% in the 1st quarter. Invesco Ltd. now owns 4,708,578 shares of the conglomerate's stock valued at $965,259,000 after buying an additional 1,450,703 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. boosted its holdings in shares of Danaher by 4.0% in the 1st quarter. Charles Schwab Investment Management Inc. now owns 4,230,087 shares of the conglomerate's stock valued at $867,168,000 after buying an additional 163,332 shares in the last quarter. 79.05% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

Several equities analysts recently commented on DHR shares. Robert W. Baird increased their price objective on shares of Danaher from $225.00 to $226.00 and gave the company an "outperform" rating in a research report on Friday, July 18th. Evercore ISI decreased their price objective on shares of Danaher from $230.00 to $226.00 and set an "outperform" rating for the company in a research report on Tuesday, July 8th. Scotiabank raised shares of Danaher from a "sector perform" rating to a "sector outperform" rating and set a $275.00 price objective for the company in a research report on Friday, July 11th. Deutsche Bank Aktiengesellschaft decreased their price objective on shares of Danaher from $240.00 to $235.00 in a research report on Thursday, June 5th. Finally, Guggenheim reaffirmed a "buy" rating and issued a $250.00 price objective on shares of Danaher in a research report on Wednesday, July 23rd. Seventeen analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company's stock. According to data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average target price of $245.91.

Insider Activity at Danaher

In other news, Director Teri List sold 2,778 shares of the firm's stock in a transaction that occurred on Friday, August 22nd. The shares were sold at an average price of $211.06, for a total transaction of $586,324.68. Following the sale, the director owned 20,751 shares of the company's stock, valued at $4,379,706.06. This trade represents a 11.81% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 11.20% of the stock is owned by insiders.

Danaher Stock Performance

DHR traded down $2.99 during trading on Monday, reaching $190.30. 2,949,617 shares of the company's stock were exchanged, compared to its average volume of 3,371,563. Danaher Corporation has a 1 year low of $171.00 and a 1 year high of $279.90. The company has a debt-to-equity ratio of 0.32, a current ratio of 1.62 and a quick ratio of 1.22. The stock has a market capitalization of $136.26 billion, a P/E ratio of 40.49, a price-to-earnings-growth ratio of 2.70 and a beta of 0.75. The company's fifty day simple moving average is $200.02 and its 200-day simple moving average is $198.03.

Danaher (NYSE:DHR - Get Free Report) last posted its quarterly earnings results on Tuesday, July 22nd. The conglomerate reported $1.80 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.64 by $0.16. Danaher had a net margin of 14.21% and a return on equity of 10.70%. The company had revenue of $5.94 billion during the quarter, compared to analyst estimates of $5.83 billion. During the same period last year, the firm posted $1.72 EPS. Danaher's revenue for the quarter was up 3.4% compared to the same quarter last year. Danaher has set its FY 2025 guidance at 7.700-7.800 EPS. As a group, research analysts predict that Danaher Corporation will post 7.63 earnings per share for the current fiscal year.

Danaher Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, October 31st. Stockholders of record on Friday, September 26th will be paid a dividend of $0.32 per share. The ex-dividend date of this dividend is Friday, September 26th. This represents a $1.28 dividend on an annualized basis and a dividend yield of 0.7%. Danaher's dividend payout ratio (DPR) is presently 27.23%.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.